A
Andrew P. Combs
Researcher at Incyte
Publications - 72
Citations - 1010
Andrew P. Combs is an academic researcher from Incyte. The author has contributed to research in topics: Cancer & Indoleamine 2,3-dioxygenase. The author has an hindex of 18, co-authored 72 publications receiving 994 citations. Previous affiliations of Andrew P. Combs include Bristol-Myers Squibb.
Papers
More filters
Journal ArticleDOI
Optimizing Preparative LC/MS Configurations and Methods for Parallel Synthesis Purification
Karl F. Blom,Sparks Richard B,James Doughty,J. Gerard Everlof,and Tasir Haque,Andrew P. Combs +5 more
TL;DR: An at-column dilution small-scale preparative LC configuration which satisfies the mass loading and small fraction volume requirements of discovery parallel synthesis schemes employing plate mapping is reported.
Patent
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase
Andrew P. Combs,Eddy W. Yue,Sparks Richard B,Wenyu Zhu,Jiacheng Zhou,Qiyan Lin,Lingkai Weng,Yue Tai-Yuen,Pingli Liu +8 more
TL;DR: In this article, the present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders.
Journal ArticleDOI
N-Arylation of α-aminoesters with p-tolylboronic acid promoted by copper(II) acetate
TL;DR: Copper-promoted Narylation of α-amino esters with p-tolylboronic acid at room temperature was accomplished with little or no racemization.
Journal ArticleDOI
Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase.
Tasir Shamsul Haque,Seifu Tadesse,Jovita Marcinkeviciene,M. John Rogers,Christine F. Sizemore,Lisa M. Kopcho,Karen Amsler,Lisa D. Ecret,Dong Liang Zhan,Frank W. Hobbs,Andrew M. Slee,George L. Trainor,Andrew M. Stern,Robert A. Copeland,Andrew P. Combs +14 more
TL;DR: The identification of several potent pyrazole-based inhibitors of bacterial dihydroorotate dehydrogenase (DHODase) via a directed parallel synthetic approach is described below.
Patent
Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors
TL;DR: In this article, the authors presented pyrrolo[2,3-b]pyridine-4-yl amines that modulate the activity of Janus kinases.